Fc Fusion Protein Market Forecast Report | Global Analysis, Statistics And Revenue Research Report by 2027

Fc Fusion Protein Market

Increasing usage of Fc fusion proteins for in vivo and in vitro research and increasing use as drugs are some key factors driving global Fc fusion protein market revenue growth 

According to the most recent analysis by Emergen Research, the market for Fc fusion proteins reached USD 26.97 billion in 2020 and is projected to grow at a rate of 10.5% during the forecast period. In vivo and in vitro research using Fc fusion proteins as well as rising drug use are two major reasons anticipated to fuel the market’s strong revenue growth over the forecast period. Between 2021 and 2028, the market’s revenue is anticipated to grow significantly due to the expanding use of Fc fusion protein in vaccines. The importance of vaccination is increasing as infectious diseases become more widespread worldwide. Going forward, it is anticipated that increased use of Fc fusion protein for vaccinations such filovirus vaccines will spur market expansion.

One major factor that is anticipated to restrain the growth of the global Fc fusion protein market to some extent in the near future is the strict rules that apply to Fc fusion protein when it is sold or used in clinical studies. Additionally, it is anticipated that the negative effects of the haemophilia drug recombinant Eloctate with Fc fusion protein may somewhat constrain market revenue growth. Due to the increasing use of Fc fusion protein for the treatment of retinal illnesses, the revenue for the eye diseases segment is anticipated to increase at a noticeably quick CAGR over the forecast period.

Get a sample of the report https://www.emergenresearch.com/request-sample/816

Over the projection period, the segment of biosimilar medications is anticipated to post a considerably strong rate of revenue growth. Biosimilars of the Fc fusion protein have been tested in numerous clinical studies for chronic diseases like HIV/AIDS, cancer, and chronic inflammatory disorders. Due to the increasing need for bio-therapeutic medications, the in vivo category is anticipated to experience considerable revenue increase throughout the forecast period. Due to the growing demand for medications based on the Fc fusion protein for the treatment of diabetes, the market in North America is anticipated to provide the biggest revenue share during the forecast period.

The global Fc fusion protein market is divided into eye illnesses, haemophilia, autoimmune disease, diabetes, and others based on therapeutic area. Due to favourable factors like an ageing population, an increase in the prevalence of diabetes worldwide, a rise in the use of Fc fusion protein in the formulation of diabetes medications, and rising investments in R&D programmes for cutting-edge diabetes therapeutics, the diabetes segment outperformed other therapeutic area segments in terms of revenue share in 2020. The global Fc fusion protein market is mainly divided into in vitro and in vivo based on application. The in vitro section is further divided into microarray technologies, immunohistochemistry, flow cytometry, and binding assays.

Some major companies in the market report include Sanofi S.A., Bristol-Myers Squibb Company, Amgen Inc., Pfizer Inc., Swedish Orphan Biovitrum AB, Eli Lilly and Company, Astellas Pharma Inc., Bayer AG, Regeneron Pharmaceuticals, Inc., and 3SBio Inc.

Emergen Research has segmented the global Fc fusion protein on the basis of type, therapeutic area, application, end-use, and region:

Type Outlook (Revenue, USD Billion; 2018–2028)

  • Biosimilar Drugs
  • Brands Drugs

Therapeutic Area Outlook (Revenue, USD Billion; 2018–2028)

  • Eye Diseases
  • Hemophilia
  • Autoimmune Disease
  • Diabetes
  • Others

Application Outlook (Revenue, USD Billion; 2018–2028)

  • In Vitro
    1. Immunohistochemistry
    2. Flow Cytometry
    3. Binding Assays
    4. Microarray Technologies
  • In Vivo
    1. Bio-therapeutic Drugs

End-Use Outlook (Revenue, USD Billion; 2018–2028)

  • Hospitals
  • Ophthalmic Hospitals
  • Oculoplastic Clinics

To know more about the report, visit https://www.emergenresearch.com/industry-report/fc-fusion-protein-market

Regional Outlook (Revenue, USD Billion; 2018–2028)

  • North America
    1. U.S.
    2. Canada
    3. Mexico
  • Europe
    1. Germany
    2. France
    3. U.K.
    4. Italy
    5. Spain
    6. BENELUX
    7. Rest of Europe
  • Asia Pacific
    1. China
    2. India
    3. Japan
    4. South Korea
    5. Rest of APAC
  • Latin America
    1. Brazil
    2. Rest of LATAM
  • Middle East & Africa
    1. Saudi Arabia
    2. UAE
    3. South Africa
    4. Turkey
    5. Rest of MEA

About Us:

Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyse consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

Contact Us:

Eric Lee

Corporate Sales Specialist

Emergen Research | Web: www.emergenresearch.com

Direct Line: +1 (604) 757-9756

E-mail: sales@emergenresearch.com

Facebook | LinkedIn | Twitter | Blogs

Latest Reports: Aerospace 3D Printing Market, Military Robots Market

Trending Reports: Medical Device Security Market, Pectin Market

You may also like...

Leave a Reply

Your email address will not be published.